Tvardi Therapeutics, Inc.
TVRD Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$0.87
KIRA · Stoqly’s AI analyst, in plain words
- Tvardi Therapeutics, Inc. lost $18.2M in fiscal 2025.
Market cap
$8.1M
P/E
21.6x
Revenue
—
Net income
−$18.2M
Free cash flow
—
Operating margin
—
Tvardi Therapeutics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$18.2M
No. It lost money last year.
How is the share priced?
21.6x
One share costs 21.6 times its yearly profit per share.
What Tvardi Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 31, 2026
- Legal name
- Tvardi Therapeutics, Inc.
- CIK
- 0001346830
Tvardi Therapeutics, Inc. · TVRD
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $23.0M | $41.9M | $21.0M | $7.1M | — |
| Revenue growth | −83.0% | 81.8% | −49.9% | −66.0% | — |
| Gross margin | 100.0% | — | — | — | — |
| Operating margin | −386.8% | −209.1% | −579.4% | −393.8% | — |
| Net income | −$88.4M | −$85.5M | −$119M | −$29.4M | −$18.2M |
| Net margin | −384.1% | −204.2% | −565.2% | −411.9% | — |
| Diluted EPS | −$1.74 | −$19.12 | −$26.26 | −$11.42 | −$3.26 |
| Cash | |||||
| Cash from operations | −$60.1M | −$78.7M | −$92.1M | −$18.3M | −$23.5M |
| Capital expenditure | $0.0M | $0.0M | $2.4M | $1.0M | — |
| Free cash flow | −$60.1M | −$78.8M | −$94.5M | −$19.4M | — |
| FCF margin | −261.1% | −188.2% | −450.5% | −271.1% | — |
| Share count change | 5.9% | −91.2% | 0.9% | −43.0% | 202.4% |
| Debt and strength | |||||
| Cash and short-term investments | $167M | $63.7M | $51.8M | $31.6M | $30.8M |
| Shareholders' equity | $228M | $159M | −$62.1M | −$91.1M | $20.9M |
| Current ratio | 9.8x | 7.2x | 4.5x | 3.1x | 2.9x |
| Returns and quality | |||||
| Return on equity | −37.1% | −44.3% | −245.1% | — | — |
| Return on tangible equity | −38.9% | −53.8% | — | — | −88.3% |
| Piotroski F-score | 1 | 3 | 1 | 4 | — |
| Altman Z'' | 7.6 | −1.0 | −20.5 | −12.3 | −10.7 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Tvardi Therapeutics, Inc. · TVRD
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.87 a share, the company is worth $8.1M: 21.6 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001346830). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.